Could a simpler Two-Drug HIV regimen be just as effective as three?
NCT ID NCT07678268
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This trial tests whether a two-drug combination (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug combination (darunavir/cobicistat plus tenofovir alafenamide/emtricitabine) in people with HIV whose virus is already suppressed. The study involves 78 adult men in Mexico who have had undetectable HIV levels for at least 48 weeks. Researchers will compare how well each regimen maintains viral suppression and monitor safety over 24 and 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Darunavir/Cobicistat plus Lamivudine
What this could lead to
If successful, this could show that a simpler two-drug HIV regimen is as effective as the standard three-drug approach, potentially reducing pill burden and side effects.
What could go wrong
This is a small pilot study with only 78 participants, all men, so results may not apply to everyone. The two-drug regimen might not suppress the virus as well as the three-drug combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital de Infectología "Dr Daniel Méndez Hernández" National Medical Center "La Raza", Instituto Mexicano del Seguro Social
RECRUITINGMexico City, Mexico City, 02990, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact